| [1] |
Liu Y, Xiang D, Zhang H, et al. Hypoxia-inducible factor-1: a potential target to treat acute lung injury[J]. Oxid Med Cell Longev,2020,2020:8871476. doi: 10.1155/2020/8871476.
|
| [2] |
Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far[J]. Front Immunol,2020,11:1446. doi:10.3389/fimmu.2020.01446.
|
| [3] |
Whyte CS, Morrow GB, Mitchell JL, et al. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19[J]. J Thromb Haemost, 2020, 18:1548-1555.
|
| [4] |
Ntatsoulis K, Karampitsakos T, Tsitoura E, et al. Commonalities between ARDS, pulmonary fibrosis and COVID-19: the potential of autotaxin as a therapeutic target[J]. Front Immunol, 2021, 12:687397. doi:10.3389/fimmu.2021.687397.
|
| [5] |
Caldarale F, Giacomelli M, Garrafa E, et al. Plasmacy-toid dendritic cells depletion and elevation of IFN-γ dependent chemokines CXCL9 and CXCL10 in children with multisystem inflammatory syndrome[J]. Front Immunol,2021, 12:654587. doi:10.3389/fimmu.2021.654587.
|
| [6] |
Callahan V, Hawks S, Crawford MA, et al. The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner[J]. Viruses, 2021, 13:1062. doi:10.3390/v13061062.
|
| [7] |
Wang W, Tan J, Xing Y, et al. p43 induces IP-10 expression through the JAK-STAT signaling pathway in HMEC-1 cells[J]. Int J Mol Med,2016,38:1217-1224.
|
| [8] |
Ichikawa A, Kuba K, Morita M, et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulmin-ant lung injury of viral and nonviral origin[J]. Am J Respir Crit Care Med, 2013, 187:65-77.
|
| [9] |
Wells A. Moreno B, Hueso L, et al. Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity[J]. Microvasc Res,2022,139:104254. doi:10.1016/j.mvr.2021.104254.
|
| [10] |
Boyé K, Billottet C, Pujol N,et al. Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR)[J]. Sci Rep, 2017, 7:10703. doi:10.1038/s41598-017-11151-x.
|
| [11] |
Pandey V, Fleming-Martinez A, Bastea L, et al. CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions[J]. Elife, 2021, 10: e60646. doi:10.7554/eLife.60646.
|
| [12] |
Zhang J, Liu Y, Chen H, et al. MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization[J]. Cell Death Dis, 2022, 13:411. doi:10.1038/s41419-022-04802-z.
|
| [13] |
Chang YS, Ko BH, Ju JC, et al. SARS unique domain (SUD) of severe acute respiratory syndrome coronavirus induces NLRP3 inflammasome-dependent CXCL10-mediated pulmonary inflammation[J]. Int J Mol Sci, 2020, 21:3179. doi:10.3390/ijms21093179.
|
| [14] |
Lupieri A, Smirnova NF, Solinhac R, et al. Smooth muscle cells-derived CXCL10 prevents endothelial healing through PI3Kγ-dependent T cells response[J]. Cardiovasc Res, 2020, 116:438-449.
|
| [15] |
Petrai I, Rombouts K, Lasagni L,et al. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B[J]. Int J Biochem Cell Biol, 2008, 40:1764-1774.
|
| [16] |
Feldman ED, Weinreich DM, Carroll NM, et al. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells[J]. Ann Surg Oncol, 2006, 13:125-133.
|
| [17] |
Mariscal A, Zamora C, Díaz-Torné C, et al. Increase of circulating monocyte-platelet conjugates in rheumatoid arthritis responders to IL-6 blockage[J]. Int J Mol Sci, 2022, 23:5748. doi:10.3390/ijms23105748.
|
| [18] |
Lou J, Hu Y, Wu MD, et al. Endothelial cell-specific anticoagulation reduces inflammation in a mouse model of acute lung injury[J]. Acta Pharmacol Sin, 2019, 40:769-780.
|
| [19] |
Ghonim MA, Boyd DF, Flerlage T, et al. Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside[J]. J Clin Invest, 2023, 133:e170499. doi:10.1172/JCI170499.
|
| [20] |
Li LF, Yu CC, Huang CY, et al. Attenuation of ventilation-enhanced epithelial-mesenchymal transition through the phosphoinositide 3-Kinase-γ in a murine bleomycin-induced acute lung injury model[J]. Int J Mol Sci, 2023, 24:5538. doi:10.3390/ijms24065538.
|
| [21] |
Jandl K, Marsh LM, Mutgan AC,et al. Impairment of the NKT-STAT1-CXCL9 axis contributes to vessel fibrosis in pulmonary hypertension caused by lung fibrosis[J]. Am J Respir Crit Care Med, 2022, 206:981-998.
|
| [22] |
Groover MK, Richmond JM. Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases[J]. F1000Res, 2020, 9:1197. doi:10.12688/f1000research.26728.1.
|
| [23] |
Dillemans L, De Somer L, Neerinckx B, et al. A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment[J]. Cell Mol Life Sci, 2023, 80:78. doi:10.1007/s00018-023-04715-w.
|
| [24] |
Cui H, Zhang Q. Dexmedetomidine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting the PI3K/Akt/FoxO1 signaling pathway[J]. J Anesth, 2021, 35:394-404.
|
